➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
Colorcon
Baxter
McKesson
Merck

Last Updated: June 3, 2020

DrugPatentWatch Database Preview

Astellas Company Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Summary for Astellas
International Patents:262
US Patents:11
Tradenames:18
Ingredients:14
NDAs:33
Patent Litigation for Astellas: See patent lawsuits for Astellas

Drugs and US Patents for Astellas

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astellas ADENOCARD adenosine INJECTABLE;INJECTION 019937-002 Oct 30, 1989 DISCN Yes No   Start Trial   Start Trial
Astellas ARISTOCORT A triamcinolone acetonide OINTMENT;TOPICAL 088780-001 Oct 1, 1984 DISCN No No   Start Trial   Start Trial
Astellas ARISTOCORT A triamcinolone acetonide OINTMENT;TOPICAL 080745-003 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
Astellas PROGRAF tacrolimus INJECTABLE;INJECTION 050709-001 Apr 8, 1994 AP RX Yes Yes   Start Trial   Start Trial
Astellas CRESEMBA isavuconazonium sulfate POWDER;INTRAVENOUS 207501-001 Mar 6, 2015 RX Yes Yes   Start Trial   Start Trial
Astellas XTANDI enzalutamide CAPSULE;ORAL 203415-001 Aug 31, 2012 RX Yes Yes 8,183,274   Start Trial   Start Trial
Astellas ARISTOCORT triamcinolone TABLET;ORAL 011161-009 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Astellas

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 9,045,519   Start Trial
Astellas VESICARE solifenacin succinate TABLET;ORAL 021518-002 Nov 19, 2004 6,017,927*PED   Start Trial
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 7,582,617   Start Trial
Astellas ADENOSCAN adenosine SOLUTION;INTRAVENOUS 020059-001 May 18, 1995 5,070,877   Start Trial
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 7,655,637   Start Trial
Astellas ASTAGRAF XL tacrolimus CAPSULE, EXTENDED RELEASE;ORAL 204096-002 Jul 19, 2013 8,551,522   Start Trial
Astellas MYCAMINE micafungin sodium INJECTABLE;INTRAVENOUS 021506-002 Mar 16, 2005 5,376,634   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for ASTELLAS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Capsules 40 mg ➤ Subscribe 2016-08-31
➤ Subscribe Injection 3 mg/mL, 20 mL and 30 mL vials ➤ Subscribe 2005-04-18
➤ Subscribe Injection 0.08 mg/mL, 5 mL vial ➤ Subscribe 2012-04-10
➤ Subscribe Extended-release Capsules 0.5 mg, 1 mg, and 5 mg ➤ Subscribe 2013-11-15
➤ Subscribe For Injection 50 mg/vial and 100 mg/vial ➤ Subscribe 2014-06-16
➤ Subscribe Injection 3 mg/mL, 20 mL and 30 mL vials ➤ Subscribe 2005-04-16
➤ Subscribe Tablets 5 mg and 10 mg ➤ Subscribe 2009-04-08

Supplementary Protection Certificates for Astellas Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1893196 491 Finland   Start Trial
1893196 SPC/GB13/079 United Kingdom   Start Trial PRODUCT NAME: ENZLUTAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/13/846 20130625
1893196 C300632 Netherlands   Start Trial PRODUCT NAME: ENZALUTAMIDE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/13/846 20130621
1189916 CA 2011 00005 Denmark   Start Trial PRODUCT NAME: REGADENOSON OG SALTE DERAF
1280795 5/2016 Austria   Start Trial PRODUCT NAME: ISAVUCONAZOL ALS ISAVUCONAZONIUMSULFAT ODER ALS EIN ISAVUCONAZONIUMSALZ MIT EINEM ANDEREN PHARMAZEUTISCH ANNEHMBAREN ANION, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, HYDRATS ODER SOLVATS; REGISTRATION NO/DATE: EU/1/15/1036 (MITTEILUNG) 20151015
1893196 CR 2013 00065 Denmark   Start Trial PRODUCT NAME: ENZALUTAMID ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/13/846 20130625
0788511 C00788511/01 Switzerland   Start Trial PRODUCT NAME: MICAFUNGIN; REGISTRATION NO/DATE: SWISSMEDIC 60724 11.07.2012
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Medtronic
Moodys
Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.